People · Operator
Named in public records as an officer, director or promoter · active 2015–2020 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Fulcrum Therapeutics, Inc. | — | Biotechnology | Series C | $183.2M | $2.8B | 2016 |
| Voyager Therapeutics, Inc. | — | Biotechnology | Series C | $119.0M | $215.1M | 2015 |
| ImmuneXcite, Inc. | — | Biotechnology | Series A | $17.6M | $96.6M | 2015 |
James Geraghty at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside James Geraghty on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Mark Levin | 2 | 9 |
| Ann DeWitt | 1 | 10 |
| Michael Higgins | 1 | 9 |
| James Collins | 1 | 8 |
| John Edwards | 1 | 8 |
| Mitchell S. Bloom | 1 | 7 |
| James Tananbaum | 1 | 6 |
| Eric Rowinsky | 1 | 4 |
| Alan Ezekowitz | 1 | 4 |
| Robert Gould | 1 | 3 |
| James A. Geraghty | 1 | 3 |
| Eric Furfine | 1 | 3 |
| Steven Paul | 1 | 3 |
| Robert W. Hesslein | 1 | 2 |
| Peter Pfreundschuh | 1 | 2 |
| Alfred Sandrock | 1 | 2 |
| Valerie Friedman | 1 | 2 |
| Todd Carter | 1 | 2 |
| Michael W. Higgins | 1 | 2 |
| Bryan Stuart | 1 | 2 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.